VivoSeq
Oncology

Myeloproliferative Neoplasms

1

Pipeline Programs↗

13

Active Trials↗

6

Companies Involved↗

Myeloproliferative Neoplasms is an early-stage landscape with 1 program across 6 companies. The most active players are Incyte, Merck & Co., Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

76/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

1 program

Phase 1Merck & Co. logo

Merck & Co.

0 programs

PreclinicalChia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

0 programs

PreclinicalP

Prelude Therapeutics

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

INCA035784

Incyte

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

31

clinical trials

Completed13 · 42%
Recruiting12 · 39%
Terminated3 · 10%
Withdrawn1 · 3%
Unknown status1 · 3%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

31 trials

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Recruiting·Incyte logoIncyte·Phase 1·NCT06313593·186 enrolled
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Recruiting·Incyte logoIncyte·Phase 1·NCT05936359·225 enrolled
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06661915·62 enrolled
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Recruiting·Incyte logoIncyte·Phase 1·NCT06034002·230 enrolled
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT06022328·120 enrolled
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Recruiting·FFox Chase Cancer Center·Phase 1·NCT06218628·24 enrolled
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
Recruiting·UUniversity of Chicago·Phase 1·NCT06291987·18 enrolled
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Recruiting·Incyte logoIncyte·Phase 1·NCT07441694·218 enrolled
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT06541249·54 enrolled
Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT07119970·300 enrolled
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Recruiting·UUniversity of California, Irvine·Phase 1/2·NCT05123365·27 enrolled
A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms
Recruiting·Incyte logoIncyte·Phase 1·NCT07008118·120 enrolled
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Not yet recruiting·PPrelude Therapeutics·Phase 1·NCT07469891·100 enrolled
An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT05223920·81 enrolled
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
Completed·—·Phase 1·NCT03566446·10 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)